April 24, 2017
The Institute for Clinical and Economic Review finds new treatments for atopic dermatitis to be cost effective – justifying health plan coverage for the medications. But methodological missteps invite questions about how secure patients’ access to the treatments will be.
April 13, 2017
What is good value in terms of cancer treatment? The question, amid rising cancer care costs, has prompted a surge of oncology value models in recent years.
April 1, 2017
Cancer treatment is better than ever before, thanks in part to more effective medications. But these medications often carry high…
March 30, 2017
Eliminating hepatitis B and C can be done, experts agree. And this week, a new report from the National Academies of Sciences, Engineering, and Medicine answers that thorny follow-up question: How?
March 28, 2017
A drug pricing watchdog group had its final say Friday on targeted arthritis treatments – and it may not be good news for patients.
February 24, 2017
The Institute for Clinical and Economic Review has issued a draft report concluding that targeted immune modulators, such as biologic treatments, for rheumatoid arthritis are too expensive. The conclusion could embolden health plans to limit patient access.
But does ICER’s model accurately reflect the experiences of the 1.5 million Americans with rheumatoid arthritis?
February 21, 2017
The Institute for Clinical and Economic Review’s newest cost-effectiveness report underscores just how far economic modeling sometimes diverges from patients’ reality, explained the Institute for Patient Access in a February 17 letter. The report analyzes rheumatoid arthritis treatments’ value by modeling expenses for simulated patients over a lifetime on certain treatments.
December 16, 2016
Hepatitis C patients keep waiting…and waiting…and waiting.
December 14, 2016
Two American public health epidemics are colliding – creating new headaches for policymakers and more heartache for communities across the country.
October 25, 2016
Evaluating cost effectiveness is one thing; using value assessments to rank patients’ treatment options is quite another.
